{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.3","upperLimit":"56.0","value":"29.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"The percent of patients where a patient experienced a Grade 3 or 4 acute GVHD","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients administered 40 mg of basiliximab as a single intravenous dose on day +7, +8, or +9 following infusion of allogeneic peripheral blood hematopoietic cells","id":"OG000","title":"Overall"}],"paramType":"NUMBER","populationDescription":"All patients enrolled and received treatment","reportingStatus":"POSTED","timeFrame":"Transplant (Day 0) up to 1 year","title":"Grade 3-4 Acute GVHD Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}